See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
Baseball
Basketball
Republican Party
Elon Musk
Hockey
US Economy
US Politics
Vladimir Putin
Senate
Military
Immigration
Published • loading... • Updated

Travere Therapeutics Q4 Adj $(0.47) Beats $(0.56) Estimate, Sales $74.79M Beat $73.34M Estimate - Travere Therapeutics (NASDAQ:TVTX)

Summary by Benzinga
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.56) by 16.07 percent. This is a 50 percent increase over losses of $(0.94) per share from

1 Articles

All
Left
Center
1
Right
BenzingaBenzinga

Travere Therapeutics Q4 Adj $(0.47) Beats $(0.56) Estimate, Sales $74.79M Beat $73.34M Estimate - Travere Therapeutics (NASDAQ:TVTX)

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.56) by 16.07 percent. This is a 50 percent increase over losses of $(0.94) per share from

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Thursday, February 20, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
Search
BlindspotLocal